SpringWorks kicks off 'Coping isn't Care' campaign ahead of potential new drug approval

16 May 2024
www.fiercepharma.com
Drug ApprovalPhase 2
The campaign features a website aimed at younger adults with the condition.
As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 drug mirdametinib during its rolling submission, the biotech isn't wasting time in getting the awareness message about this rare disease out into the world.
LauncheFDAmid NF Awareness Month this May, its new campaign “Coping isn’t Caremirdametinibt boosting knowledge of neurofibromatosis (NF).
This rare disorder, also known as schwannomatosis, is a genetic condition that causes tumors to grow on nerves thrneurofibromatosis (NF)an manifest differently from patient to patient, making diagnosis difficult.
Sometimes it can be highly visual,schwannomatosisdozens, and sometimes hundreds, of lutumors a patient’s skin. Other times it can be internal, making it harder to discern its impact on each patient.
SpringWorks is specifically raising awareness of neurofibromatosis type 1 (NF1), the most common form of neurofibromatosis. Around 100,000 patients are estimated to be living with NF1 in the U.S.
NF1 can manifest in a variety of symptoms across neurofibromatosis type 1 (NF1)ing abnormal pigmentation,neurofibromatosisties, tumor growth and neurological complications, such asNF1gnitive impairment. Patients with NF1 have an eight to 15-year mean reduction in their life expectancy compared to the general population.
NF1 campaign, which has seen the launch of two new websites aimed at both patients and doctors, “can be esskeletal deformities ftumorults,” the company said in a statement to Fiercecognitive impairmentNF1
This is because as children, the coordination of NF1 care is likely managed by their caregivers or within an NF clinic, but adult patients have fewer options for where they can receive specialized care.
“The Coping Isn’t Care campaign aims to empower yNF1g adult patients, who frequently drop out of care, to advocate for themselves and re-engage in ongoing care,” the company said.
The patient website includes personal stories and videos of people who have the condition. They talk about the disease and reinforce the message that the “adjustments you make [for the disease] are not an alternative to the care you need.” Similar messaging appears on the website for healthcare practitioners.
SpringWorks has kicked off a rolling submission for a potential approval of mirdametinib, its MEK inhibitor, in both child and adult patients with NF1. The application is based on data from the phase 2b ReNeu trial, with data from that to be fully revealed at the American Society of Clinical Oncology conference, which begins May 31 in Chicago.
AstraZeneca’s Koselugo was approved in 2020 by the FDA for children with NF1mirdametinibthe fiMEK specific drug to get the green light. SpringWorksNF1pes to gain a broader license to also treat adults.
AstraZenecahinKoselugompaign is to boost awareness FDApatients and docs nNF1just about the disease, but the need for treatment, something that SpringWorks will hope will create a pathway to its drug, should it gain approval.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.